Centivax is a biotechnology company that develops vaccines and therapeutic antibodies targeting infectious diseases and venomous threats.
Centivax has raised $37.0M in total funding. The most recent round was Series Unknown. The last funding was announced in March 2026.
Centivax's investors include Structure Fund, Bill & Melinda Gates Foundation, NFX, Future Ventures, Amplify Partners.
Centivax is headquartered in South San Francisco, United States.
Centivax is a biotechnology company that develops vaccines and therapeutic antibodies targeting infectious diseases and venomous threats.
Centivax is at the Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Centivax — Funding & Investors." VCBacked, March 30, 2026, https://www.vcbacked.co/company/centivax. Accessed August 16, 2026.
VCBacked. (2026). Centivax — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/centivax
{{cite web |title=Centivax — Funding & Investors |url=https://www.vcbacked.co/company/centivax |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated